Article Sidebar

PDF
Date Published: 22/06/2022
Abstract Views: 300
Views PDF: 370
DOI: https://doi.org/10.51298/vmj.v515i1.2717
Issue
Vol. 515 No. 1 (2022)
Section
Các bài báo
How to Cite
Thị Diệu Ngân, Đào ., Thanh Sang, H. ., Ngọc Khôi, N. ., & Như Hồ, N. . (2022). INVESTIGATION ON GLUCOCORTICOID THERAPY FOR OUTPATIENTS USING GLUCOCORTICOID ORAL FOR 3 MONTHS OR MORE AT GIA DINH PEOPLE’S HOSPITAL. Vietnam Medical Journal, 515(1). https://doi.org/10.51298/vmj.v515i1.2717

INVESTIGATION ON GLUCOCORTICOID THERAPY FOR OUTPATIENTS USING GLUCOCORTICOID ORAL FOR 3 MONTHS OR MORE AT GIA DINH PEOPLE’S HOSPITAL

Đào Thị Diệu Ngân1, Huỳnh Thanh Sang2, Nguyễn Ngọc Khôi3, Nguyễn Như Hồ3,
1 Ninh Thuan General Hospital
2 Ho Chi Minh City University of Technology
3 University of Medicine and Pharmacy at Ho Chi Minh city

Main Article Content

Abstract

Objective: To report on adverse drug events (ADEs) in adults using glucocorticosteroids (GCs) for 3 months or more. Subjects and methods: A cross - sectional study was conducted on outpatients with people from 18 – 80 years old at Gia Dinh People’s Hospital between October 2020 and March 2021. Collected data for analysis included patient characteristics, pattern of systemic GCs uses, ADEs and associated factors. Results: We interviewed 157 patients about ADEs during their course of GC therapy. The median age of this group was 60 and most of them were female (64,1%). More than half of the patients (59,9%) reported using GCs for more than 12 months. Many patients with adrenal insufficiency were indicated GCs as replacement therapies (38,2%). Cushing’s syndrome was the most frequent adverse event (55,4%). Gender was associated with Cushing’s syndrome (OR = 2,72; 95% CI, 1,32 - 5,58) in patients with long – term use of GC. Conclusions: It is necessary to monitor closely outpatients prescribed with GCs in order to limit adverse events

Article Details

Keywords

glucocorticoid, outpatient, adverse events, long – term

References

1. Liu D., Ahmet A., Ward L. et al. (2013), "A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy", Allergy Asthma Clin Immunol, 9 (30), doi:10.1186/1710-1492-9-30.
2. Fardet L., Petersen I. , Nazareth I. J. R. (2011), "Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years", Rheumatology 50 (11), p. 1982-1990.
3. Curtis J. R., Westfall A. O., Allison J. J. et al. (2005), "Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients", Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 52 (8), p. 2485-2494.
4. Overman R. A., Yeh J.-Y. , Deal C. L. (2013), "Prevalence of oral glucocorticoid usage in the United States: A general population perspective", Arthritis care & Research 65 (2), p. 294-298.
5. Fardet L., Flahault A., Kettaneh A. et al. (2007), "Corticosteroid‐induced clinical adverse events: frequency, risk factors and patient’s opinion", British Journal of Dermatology 157 (1), p. 142-148.
6. Pivonello R., De Martino M. C., De Leo M. et al. (2008), "Cushing's Syndrome", Endocrinology and metabolism clinics of North America,, 37 (1), p. 135-149.